Stem cell therapy in osteoarthritis: A step too far?

BioDrugs

Volumn 27, Issue 3, 2013, Pages 175-180

  Van Der Kraan, Peter M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE; HYALURONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL;

CANCER GROWTH; CELL CULTURE; CELL MIGRATION; FOLLOW UP; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; OSTEOARTHRITIS; PATIENT SAFETY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THERAPY EFFECT; TISSUE REGENERATION;

ARTHROPLASTY, REPLACEMENT; HUMANS; INFLAMMATION MEDIATORS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OSTEOARTHRITIS; RISK FACTORS;

EID: 84878560368     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0017-6     Document Type: Review

References (65)

1. Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res 2004;(427 Suppl.):S6-15.
2. Suri P, Morgenroth DC, Hunter DJ. Epidemiology of osteoarthritis and associated comorbidities. PM R. 2012;4(5 Suppl.):S10-9.
3. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697-707.
4. Haugen IK, Boyesen P, Slatkowsky-Christensen B, Sesseng S, van der Heijde D, Kvien TK. Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis. Ann Rheum Dis. 2012;71(6):899-904.
5. Zhang Y, Nevitt M, Niu J, Lewis C, Torner J, Guermazi A, et al. Fluctuation of knee pain and changes in bone marrow lesions, effusions, and synovitis on magnetic resonance imaging. Arthritis Rheum. 2011;63(3):691-9.
6. Hunter W. Of the structure and disease of articulating cartilages, 1743. Clin Orthop Relat Res. 1995;317:3-6.
7. Dell'Accio F, Vincent TL. Joint surface defects: clinical course and cellular response in spontaneous and experimental lesions. Eur Cell Mater. 2010;20:210-7.
8. Bedi A, Feeley BT, Williams RJ III. Management of articular cartilage defects of the knee. J Bone Joint Surg Am. 2010;92(4):994-1009.
9. Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol. 2007;25(10):1177-81. (Pubitemid 47538112)
10. Qi H, Pei D. The magic of four: induction of pluripotent stem cells from somatic cells by Oct4, Sox2, Myc and Klf4. Cell Res. 2007;17(7):578-80. (Pubitemid 47116353)
11. Ladenstein R, Peters C, Gadner H. The present role of bone marrow and stem cell transplantation in the therapy of children with acute leukemia. Ann N Y Acad Sci. 1997;824:38-64. (Pubitemid 27480393)
12. Spencer ND, Gimble JM, Lopez MJ. Mesenchymal stromal cells: past, present, and future. Vet Surg. 2011;40(2):129-39.
13. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol. 1976;47:327-59.
14. Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, et al. Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells. 2011;29(5):871-82.
15. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7. (Pubitemid 44269669)
16. Mohal JS, Tailor HD, Khan WS. Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications. Curr Stem Cell Res Ther. 2012;7(2):103-9.
17. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol. 2007;211(1):27-35. (Pubitemid 46363893)
18. Tadokoro M, Kanai R, Taketani T, Uchio Y, Yamaguchi S, Ohgushi H. New bone formation by allogeneic mesenchymal stem cell transplantation in a patient with perinatal hypophosphatasia. J Pediatr. 2009;154(6):924-30.
19. Jones E, Yang X. Mesenchymal stem cells and bone regeneration: current status. Injury. 2011;42(6):562-8.
20. Koga H, Engebretsen L, Brinchmann JE, Muneta T, Sekiya I. Mesenchymal stem cell-based therapy for cartilage repair: a review. Knee Surg Sports Traumatol Arthrosc. 2009;17(11):1289-97.
21. Noth U, Steinert AF, Tuan RS. Technology insight: adult mesenchymal stem cells for osteoarthritis therapy. Nat Clin Pract Rheumatol. 2008;4(7):371-80. (Pubitemid 351974009)
22. Wakitani S, Kimura T, Hirooka A, Ochi T, Yoneda M, Yasui N, et al. Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel. J Bone Joint Surg Br. 1989;71(1):74-80. (Pubitemid 19049585)
23. Freed LE, Vunjak-Novakovic G, Langer R. Cultivation of cell-polymer cartilage implants in bioreactors. J Cell Biochem. 1993;51(3):257-64. (Pubitemid 23103601)
24. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003;48(12):3464-74. (Pubitemid 37531912)
25. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis: preliminary report of four patients. Int J Rheum Dis. 2011;14(2):211-5.
26. Varma HS, Dadarya B, Vidyarthi A. The new avenues in the management of osteo-arthritis of knee: stem cells. J Indian Med Assoc. 2010;108(9):583-5.
27. Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells. Med Hypotheses. 2008;71(6):900-8.
28. Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008;11(3):343-53. (Pubitemid 351959424)
29. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol. 1996;166(3):585-92. (Pubitemid 26095485)
30. Wu L, Leijten JC, Georgi N, Post JN, van Blitterswijk CA, Karperien M. Trophic effects of mesenchymal stem cells increase chondrocyte proliferation and matrix formation. Tissue Eng Part A. 2011;17(9-10):1425-36.
31. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815-22. (Pubitemid 40223708)
32. El-Badri NS, Maheshwari A, Sanberg PR. Mesenchymal stem cells in autoimmune disease. Stem Cells Dev. 2004;13(5):463-72. (Pubitemid 39473577)
33. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007;56(4):1175-86. (Pubitemid 46608642)
34. Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum. 2005;52(5):1595-603. (Pubitemid 40663952)
35. Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol. 2007;179(3):1595-604.
36. Black LL, Gaynor J, Adams C, Dhupa S, Sams AE, Taylor R, et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther. 2008;9(3):192-200.
37. Black LL, Gaynor J, Gahring D, Adams C, Aron D, Harman S, et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther. 2007;8(4):272-84. (Pubitemid 351419393)
38. Glynn SA, Busch MP, Dodd RY, Katz LM, Stramer SL, Klein HG, et al. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion. 2013;53(2):438-54.
39. Li XY, Ding J, Zheng ZH, Li XY, Wu ZB, Zhu P. Long-term culture in vitro impairs the immunosuppressive activity of mesenchymal stem cells on T cells. Mol Med Report. 2012;6(5):1183-9.
40. Stolzing A, Coleman N, Scutt A. Glucose-induced replicative senescence in mesenchymal stem cells. Rejuvenation Res. 2006;9(1):31-5.
41. Blaha M, Mericka P, Stepanova V, Splino M, Maly J, Jebavy L, et al. Prevention of infection transmission during stem cell transplantation. Folia Microbiol (Praha). 2006;51(6):609-13. (Pubitemid 46292270)
42. Ho AD, Wagner W, Franke W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy. 2008;10(4):320-30. (Pubitemid 351983156)
43. Sensebe L, Bourin P, Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther. 2011;22(1):19-26.
44. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;26(2):8. (Pubitemid 41364607)
45. Rossignol J, Boyer C, Thinard R, Remy S, Dugast AS, Dubayle D, et al. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med 2009;13(8B):2547-58.
46. Mishima Y, Lotz M. Chemotaxis of human articular chondrocytes and mesenchymal stem cells. J Orthop Res. 2008;26(10):1407-12.
47. Baragi VM, Renkiewicz RR, Qiu L, Brammer D, Riley JM, Sigler RE, et al. Transplantation of adenovirally transduced allogeneic chondrocytes into articular cartilage defects in vivo. Osteoarthr Cartil. 1997;5(4):275-82. (Pubitemid 27315906)
48. Kang R, Marui T, Ghivizzani SC, Nita IM, Georgescu HI, Suh JK, et al. Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study. Osteoarthr Cartil. 1997;5(2):139-43. (Pubitemid 27141777)
49. Wood JA, Chung DJ, Park SA, Zwingenberger AL, Reilly CM, Ly I, et al. Periocular and intra-articular injection of canine adipose-derived mesenchymal stem cells: an in vivo imaging and migration study. J Ocul Pharmacol Ther. 2012;28(3):307-17.
50. Perrot P, Heymann D, Charrier C, Couillaud S, Redini F, Duteille F. Extraosseous bone formation obtained by association of mesenchymal stem cells with a periosteal flap in the rat. Ann Plast Surg. 2007;59(2):201-6. (Pubitemid 47220426)
51. Pelttari K, Winter A, Steck E, Goetzke K, Hennig T, Ochs BG, et al. Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. Arthritis Rheum. 2006;54(10):3254-66. (Pubitemid 44622096)
52. Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110(4):1362-9. (Pubitemid 47281438)
53. Hellingman CA, Davidson EN, Koevoet W, Vitters EL, van den Berg WB, van Osch GJ, et al. Smad signaling determines chondrogenic differentiation of bone-marrow-derived mesenchymal stem cells: inhibition of Smad1/5/8P prevents terminal differentiation and calcification. Tissue Eng Part A. 2011;17(7-8):1157-67.
54. Kafienah W, Jakob M, Demarteau O, Frazer A, Barker MD, Martin I, et al. Three-dimensional tissue engineering of hyaline cartilage: comparison of adult nasal and articular chondrocytes. Tissue Eng. 2002;8(5):817-26. (Pubitemid 35239759)
55. Wang D, Wang S, Shi C. Update on cancer related issues of mesenchymal stem cell-based therapies. Curr Stem Cell Res Ther. 2012;7(5):370-80.
56. Tasso R, Augello A, Carida' M, Postiglione F, Tibiletti MG, Bernasconi B, et al. Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds. Carcinogenesis. 2009;30(1):150-7.
57. Akay I, Oxmann D, Helfenstein A, Mentlein R, Schunke M, Hassenpflug J, et al. Tumor risk by tissue engineering: cartilaginous differentiation of mesenchymal stem cells reduces tumor growth. Osteoarthr Cartil. 2010;18(3):389-96.
58. Donnenberg VS, Zimmerlin L, Rubin JP, Donnenberg AD. Regenerative therapy after cancer: what are the risks? Tissue Eng Part B Rev. 2010;16(6):567-75.
59. Pinilla S, Alt E, Abdul Khalek FJ, Jotzu C, Muehlberg F, Beckmann C, et al. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett. 2009;284(1):80-5.
60. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer. 2010;9:129.
61. Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res. 2011;108(11):1340-7.
62. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, et al. Spontaneous human adult stem cell transformation. Cancer Res. 2005;65(8):3035-9. (Pubitemid 40524580)
63. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12(5):576-8.
64. Ben-David U, Mayshar Y, Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell. 2011;9(2):97-102.
65. Wong RS. Mesenchymal stem cells: angels or demons? J Biomed Biotechnol 2011;2011:459510. doi: 10.1155/2011/459510.